Showing 5541-5560 of 8875 for: Cochrane Systematic Reviews Back
- Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults
Cochrane Systematic Reviews, 21-Sep-2018
Olanzapine as an antiemetic represents a new use of an antipsychotic drug. People with cancer may experience nausea and vomiting whilst receiving chemotherapy or radiotherapy, or whilst in the palliative phase of illness.
- Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses
Cochrane Systematic Reviews, 4-Aug-2009
People presenting with agitated or violent behaviour thought to be due to severe mental illness may require urgent pharmacological tranquillisation. Several preparations of olanzapine, an antipsychotic drug, are now being used for management of such agita
- Olanzapine in long‐term treatment for bipolar disorder
Cochrane Systematic Reviews, 21-Jan-2009
Many patients with bipolar disorder require long-term treatment to prevent recurrence. Antipsychotic drugs are often used to treat acute manic episodes. It is important to clarify whether olanzapine could have a role in long-term prevention of manic and d
- Olanzapine versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 1-May-2013
In many countries of the industrialised world second generation ("atypical") antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generati
- Omalizumab for asthma in adults and children
Cochrane Systematic Reviews, 18-Dec-2013
Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It
- Omega 3 fatty acid for the prevention of cognitive decline and dementia
Cochrane Systematic Reviews, 14-Aug-2012
Evidence from observational studies suggests that diets high in omega-3 long-chain polyunsaturated fatty acids (PUFA) may protect people from cognitive decline and dementia. The strength of this potential protective effect has recently been tested in rand
- Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease
Cochrane Systematic Reviews, 28-Feb-2014
The anti-inflammatory effects of n-3 (omega-3 fatty acids, fish oil) have been suggested to be beneficial in chronic inflammatory disorders such as inflammatory bowel disease. This review is an update of a previously published Cochrane review.
- Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis
Cochrane Systematic Reviews, 27-May-2008
Omega-3 fatty acids (n-3, fish oil) have been shown to have anti-inflammatory properties. Therefore, n-3 therapy may be beneficial in chronic inflammatory disorders such as ulcerative colitis.
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration
Cochrane Systematic Reviews, 9-Apr-2015
Evidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease
Cochrane Systematic Reviews, 18-Dec-2019
Polyunsaturated fatty acid (PUFA) supplements, involving omega-3 and/or omega-6 components, have been proposed as a therapy for dry eye. Omega-3 PUFAs exist in both short- (alpha-linolenic acid [ALA]) and long-chain (eicosapentaenoic acid [EPA] and docosa
- Omega‐3 fatty acid addition during pregnancy
Cochrane Systematic Reviews, 15-Nov-2018
Higher intakes of foods containing omega-3 long-chain polyunsaturated fatty acids (LCPUFA), such as fish, during pregnancy have been associated with longer gestations and improved perinatal outcomes. This is an update of a review that was first published
- Omega‐3 fatty acid supplementation for cystic fibrosis
Cochrane Systematic Reviews, 10-Apr-2020
Studies suggest that a diet rich in omega-3 essential fatty acids may have beneficial anti-inflammatory effects for chronic conditions such as cystic fibrosis. This is an updated version of a previously published review.
- Omega-3 fatty acids for bipolar disorder
Cochrane Systematic Reviews, 2-Nov-2008
Bipolar disorder is a complex psychiatric disorder and is amongst the top thirty causes of worldwide disability. Mood stabilisers are the primary pharmacological intervention, both in the treatment of acute episodes and in prophylaxis. There is, however,
- Omega‐3 fatty acids for depression in adults
Cochrane Systematic Reviews, 24-Nov-2021
Major depressive disorder (MDD) is highly debilitating, difficult to treat, has a high rate of recurrence, and negatively impacts the individual and society as a whole. One potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also kn
- Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
Cochrane Systematic Reviews, 18-Nov-2018
Maintaining long-term vascular access patency is necessary for high quality haemodialysis (HD) treatment of patients with the terminal and most serious stage of chronic kidney disease (CKD) - end-stage kidney disease (ESKD). Oral supplementation with omeg
- Omega-3 fatty acids for intermittent claudication
Cochrane Systematic Reviews, 3-Jul-2013
Omega-3 fatty acids have been used in the treatment and prevention of coronary artery disease although current evidence suggests they may be of limited benefit. Peripheral arterial disease and coronary artery disease share a similar pathogenesis so omega-
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
Cochrane Systematic Reviews, 29-Feb-2020
Omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3)), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) may benefit cardiovascular health. Guidelines recomm
- Omega‐3 fatty acids for the treatment of dementia
Cochrane Systematic Reviews, 11-Apr-2016
Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish and plant sources are commonly considered as a promising non-medical alternative to improve brain functions and slow down the progression of dementia. This assumption is mostly based on finding
- Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)
Cochrane Systematic Reviews, 31-Oct-2011
It has been suggested that impairments associated with autism spectrum disorders (ASD) may be partially explained by deficits of omega-3 fatty acids, and that supplementation of these essential fatty acids may lead to improvement of symptoms.
- Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus
Cochrane Systematic Reviews, 4-Nov-2008
People with type 2 diabetes mellitus are at increased risk from cardiovascular disease. Dietary omega-3 polyunsaturated fatty acids (PUFAs) are known to reduce triglyceride levels, but their impact on cholesterol levels, glycemic control and vascular outc
